Serlopitant is a small molecule antagonist of neurokinin-1 (NK1-R), the primary endogenous receptor for the neuropeptide, Substance P (SP). The importance of SP and NK1 receptor as mediators of pruritus and cough signaling were demonstrated in multiple animal models and human clinical trials1-2. Serlopitant is administered orally once daily. Serlopitant has been administered to over 1000 individuals to date and has shown benefit in two completed phase 2 studies in pruritic conditions.

1 Lavinka and Dong, “Molecular Signaling and Targets from Itch: Lessons for Cough.” 
2 M. Grobman and C. Reinero, “Investigation of Neurokinin-1 Receptor Antagonism as a Novel Treatment for Chronic Bronchitis in Dogs,” J Vet Intern Med  (2016).